Moat Ross 4
4 · Kiniksa Pharmaceuticals International, plc · Filed Jun 5, 2025
Insider Transaction Report
Form 4
Moat Ross
CHIEF COMMERCIAL OFFICER
Transactions
- Sale
Class A Ordinary Share
2025-06-03$29.02/sh−27,594$800,778→ 9,415 total - Exercise/Conversion
Class A Ordinary Share
2025-06-03$13.35/sh+27,594$368,380→ 37,009 total - Exercise/Conversion
Share Option
2025-06-03−27,594→ 0 totalExercise: $13.35Exp: 2029-06-30→ Class A Ordinary Share (27,594 underlying)
Footnotes (3)
- [F1]This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on November 13, 2024.
- [F2]This transaction was executed in multiple trades through a broker-dealer at prices ranging between $29.00 and $29.115. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
- [F3]The option is fully vested and exercisable.